卵巢癌腹膜转移腹腔化疗的研究进展

doi:10.12280/gjszjk.20210481

摘要/Abstract

摘要：

卵巢癌早期临床症状不明显,确诊时多为晚期,约75%的患者发生腹膜转移,手术难以完全清除肿瘤病灶,治疗效果差,易复发,死亡率高居所有妇科恶性肿瘤首位。晚期卵巢癌腹膜转移患者常伴有不同程度的癌性腹腔积液,多以控制局部发展为主要治疗目标,因此肿瘤细胞减灭术及腹腔注射化疗药物成为此类患者的主要治疗方式。与常规静脉应用化疗药物相比,腹腔热灌注化疗、加压腹腔气溶胶化疗等腹腔化疗方式在缩小肿瘤体积、控制恶性腹腔积液方面有突出优势,能够显著延长卵巢癌患者无复发生存期、无病生存期及总生存期,同时减轻治疗相关不良反应,提高患者的生存质量。综述卵巢癌腹腔化疗及其临床研究进展,以期为临床治疗提供参考。

关键词: 卵巢肿瘤, 腹膜肿瘤, 肿瘤转移, 注射,腹腔内, 药物疗法

Abstract:

The early clinical symptoms of ovarian cancer are not obvious, and most of the patients have been at the advanced stage when they were diagnosed. About 75% of patients have the peritoneal metastases of ovarian cancer which are difficult to be resected completely by surgery. The therapeutic effect of metastasizing neoplasms is poor, and neoplasm is prone to recur. The mortality rate is the first of all gynecological malignancies. Patients with the advanced ovarian cancer and the peritoneal metastasis are often accompanied by different degrees of cancerous peritoneal effusion, and the main treatment goal is to control local development. Therefore, cytoreductive surgery and intraperitoneal injection of chemotherapy drugs are of important treatment methods for those patients with peritoneal metastasis of ovarian cancer. Compared with the conventional intravenous chemotherapy, intraperitoneal chemotherapy methods such as hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) have outstanding advantages in reducing tumor volume and controlling malignant peritoneal effusion, which can significantly prolong recurrence-free survival (RFS), disease-free survival (DFS) and overall survival (OS) of patients. Meanwhile, the intraperitoneal chemotherapy methods reduce treatment-related adverse reactions, and improve life quality of patients. This paper reviews the intraperitoneal chemotherapy methods of the peritoneal metastases of ovarian cancer and the research progress, in order to provide a reference for clinical treatment.

Key words: Ovarian neoplasms, Peritoneal neoplasms, Neoplasm metastases, Injections,intraperitoneal, Drug therapy

安亚丽, 张廷凤, 许丽, 杨永秀. 卵巢癌腹膜转移腹腔化疗的研究进展[J]. 国际生殖健康/计划生育, 2022, 41(1): 79-83.

AN Ya-li, ZHANG Ting-feng, XU Li, YANG Yong-xiu. Research Progress of Intraperitoneal Chemotherapy for Peritoneal Metastases of Ovarian Cancer[J]. Journal of International Reproductive Health/Family Planning, 2022, 41(1): 79-83.

参考文献 35

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics,2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. doi: 10.3322/caac.21590. doi: 10.3322/caac.21590 URL
[2]	Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. doi: 10.1016/j.bpobgyn.2016.08.006 URL
[3]	孙庆娥, 黄晓燕, 刘海宁. 腹腔热灌注疗法对上皮性卵巢癌腹腔转移患者治疗效果的影响[J]. 癌症进展, 2019, 17(1):86-89. doi: 10.11877/j.issn.1672-1535.2019.17.01.23. doi: 10.11877/j.issn.1672-1535.2019.17.01.23
[4]	Marrelli D, Petrioli R, Cassetti D, et al. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer[J]. Surg Oncol, 2021, 37:101523. doi: 10.1016/j.suronc.2021.101523. doi: 10.1016/j.suronc.2021.101523 pmid: 33545658
[5]	朱俊, 吴小华. 2020年度妇科恶性肿瘤最新研究进展及展望[J]. 中国癌症杂志, 2021, 31(4):250-256. doi: 10.19401/j.cnki.1007-3639.2021.04.002. doi: 10.19401/j.cnki.1007-3639.2021.04.002
[6]	Sarkar S, Malekshah OM, Nomani A, et al. A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer[J]. Cancer Med, 2018, 7(8):3630-3641. doi: 10.1002/cam4.1631. doi: 10.1002/cam4.1631 URL
[7]	Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer[J]. Ann Oncol, 2017, 28(Suppl_8):viii61-viii65. doi: 10.1093/annonc/mdx443. doi: 10.1093/annonc/mdx443
[8]	Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline[J]. Gynecol Oncol, 2016, 143(1):3-15. doi: 10.1016/j.ygyno.2016.05.022. doi: S0090-8258(16)30751-X pmid: 27650684
[9]	van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer[J]. N Engl J Med, 2018, 378(3):230-240. doi: 10.1056/NEJMoa1708618. doi: 10.1056/NEJMoa1708618 URL
[10]	Gadducci A, Carnino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest[J]. Gynecol Oncol, 2000, 76(2):157-162. doi: 10.1006/gyno.1999.5677. doi: 10.1006/gyno.1999.5677 pmid: 10637064
[11]	Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study[J]. J Clin Oncol, 2015, 33(13):1460-1466. doi: 10.1200/JCO.2014.55.9898. doi: 10.1200/JCO.2014.55.9898 URL
[12]	卢淮武, 许妙纯, 张钰豪, 等. 《2021 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(4):457-466. doi: 10.19538/j.fk2021040113. doi: 10.19538/j.fk2021040113
[13]	Kim SR, Maganti M, Bernardini MQ, et al. Efficacy and toxicity of intraperitoneal chemotherapy as compared to intravenous chemotherapy in the treatment of patients with advanced ovarian cancer[J]. Int J Gynaecol Obstet, 2021 Jul 2. doi: 10.1002/ijgo.13813. doi: 10.1002/ijgo.13813
[14]	中国抗癌协会妇科肿瘤专业委员会, 中国妇科腹腔热灌注化疗技术临床应用专家协作组. 妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019)[J]. 中国实用妇科与产科杂志, 2019, 35(2):194-201. doi: 10.19538/j.fk2019020116. doi: 10.19538/j.fk2019020116
[15]	Muller M, Chérel M, Dupré PF, et al. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study[J]. Eur Surg Res, 2011, 46(3):139-147. doi: 10.1159/000324395. doi: 10.1159/000324395 URL
[16]	Zunino B, Rubio-Patiño C, Villa E, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90[J]. Oncogene, 2016, 35(2):261-268. doi: 10.1038/onc.2015.82. doi: 10.1038/onc.2015.82 pmid: 25867070
[17]	Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. ESMO Open, 2021, 6(3):100149. doi: 10.1016/j.esmoop.2021.100149. doi: 10.1016/j.esmoop.2021.100149 pmid: 33984680
[18]	Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study[J]. Ann Surg Oncol, 2015, 22(5):1570-1575. doi: 10.1245/s10434-014-4157-9. doi: 10.1245/s10434-014-4157-9 pmid: 25391263
[19]	Kim SI, Cho J, Lee EJ, et al. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis[J]. Medicine(Baltimore), 2019, 98(50):e18355. doi: 10.1097/MD.0000000000018355. doi: 10.1097/MD.0000000000018355
[20]	Zhang G, Zhu Y, Liu C, et al. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis[J]. J Ovarian Res, 2019, 12(1):33. doi: 10.1186/s13048-019-0509-1. doi: 10.1186/s13048-019-0509-1 pmid: 30995948
[21]	Carboni F, Federici O, Sperduti I, et al. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience[J]. Cancers(Basel), 2021, 13(3):523. doi: 10.3390/cancers13030523. doi: 10.3390/cancers13030523
[22]	Glennon K, Mulligan K, Carpenter K, et al. The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer[J]. Gynecol Oncol Rep, 2021, 37:100796. doi: 10.1016/j.gore.2021.100796. doi: 10.1016/j.gore.2021.100796
[23]	Oh S, Paik H, Park SJ, et al. Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review[J]. Gland Surg, 2021, 10(3):1244-1251. doi: 10.21037/gs-2019-ursoc-12. doi: 10.21037/gs-2019-ursoc-12 URL
[24]	Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377. doi: 10.1016/S1470-2045(19)30318-3. doi: 10.1016/S1470-2045(19)30318-3 URL
[25]	Robella M, De Simone M, Berchialla P, et al. A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis[J]. Cancers(Basel), 2021, 13(5):1060. doi: 10.3390/cancers13051060. doi: 10.3390/cancers13051060
[26]	Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis[J]. Eur J Surg Oncol, 2017, 43(11):2178-2183. doi: 10.1016/j.ejso.2017.09.010. doi: 10.1016/j.ejso.2017.09.010 URL
[27]	Tempfer CB. Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis[J]. Med Hypotheses, 2015, 85(4):480-484. doi: 10.1016/j.mehy.2015.07.001. doi: 10.1016/j.mehy.2015.07.001 URL
[28]	Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC)[J]. Eur J Surg Oncol, 2015, 41(10):1379-1385. doi: 10.1016/j.ejso.2015. 06.001. doi: 10.1016/j.ejso.2015.06.001 pmid: 26138283
[29]	Shariati M, Lollo G, Matha K, et al. Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer[J]. ACS Appl Mater Interfaces, 2020, 12(26):29024-29036. doi: 10.1021/acsami.0c05554. doi: 10.1021/acsami.0c05554
[30]	Park SJ, Lee EJ, Lee HS, et al. Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum[J]. Drug Deliv, 2021, 28(1):1179-1187. doi: 10.1080/10717544.2021.1937382. doi: 10.1080/10717544.2021.1937382 pmid: 34121568
[31]	Bachmann C, Sautkin I, Nadiradze G, et al. Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC)[J]. Surg Endosc, 2021, 35(11):6358-6365. doi: 10.1007/s00464-021-08567-y. doi: 10.1007/s00464-021-08567-y pmid: 34114069
[32]	Kakchekeeva T, Demtröder C, Herath NI, et al. In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC)[J]. Ann Surg Oncol, 2016, 23(Suppl 5):592-598. doi: 10.1245/s10434-016-5108-4. doi: 10.1245/s10434-016-5108-4 pmid: 26842487
[33]	Willaert W, Van de Sande L, Van Daele E, et al. Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis[J]. Eur J Surg Oncol, 2019, 45(12):2302-2309. doi: 10.1016/j.ejso.2019.06.018. doi: S0748-7983(19)30512-8 pmid: 31221459
[34]	Taibi A, Teixeira Farinha H, Durand Fontanier S, et al. Pressurized Intraperitoneal Aerosol Chemotherapy Enhanced by Electrostatic Precipitation (ePIPAC) for Patients with Peritoneal Metastases[J]. Ann Surg Oncol, 2021, 28(7):3852-3860. doi: 10.1245/s10434-020-09332-6. doi: 10.1245/s10434-020-09332-6 URL
[35]	Minchinton AI, Tannock IF. Drug penetration in solid tumours[J]. Nat Rev Cancer, 2006, 6(8):583-592. doi: 10.1038/nrc1893. doi: 10.1038/nrc1893 pmid: 16862189